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Abstract
Background: Ovarian carcinoma (OvCa) is the most lethal gynecological malignancy among women and its poor
prognosis is mainly due to metastasis. Chemokine receptor CCR9 is primarily expressed by a small subset of
immune cells and its only natural ligand, CCL25, is largely expressed in the thymus, which involutes with age.
Other than the thymus, CCL25 is expressed by the small bowel. Interactions between CCL25 and CCR9 have been
implicated in leukocyte trafficking to the small bowel, a frequent metastatic site for OvCa cells. The current study
shows OvCa tissue and cells significantly express CCR9, which interacts with CCL25 to support carcinoma cell
migration and invasion.
Methods: RT-PCR and flow cytometry techniques were used to quantify the expression CCR9 by OvCa cells. OvCa
tissue microarrays (TMA) was used to confirm CCR9 expression in clinical samples. The Aperio ScanScope scanning
system was used to quantify immunohistochemical staining. Cell invasion and migration assays were performed
using cell migration and matrigel invasion chambers. Matrix metalloproteinase (MMP) mRNAs were quantified by
RT-PCR and active MMPs were quantified by ELISA.
Results: Our results show significantly (p < 0.001) higher expression of CCR9 by mucinous adenocarcinoma,
papillary serous carcinoma, and endometriod ovarian carcinoma cases, than compared to non-neoplastic ovarian
tissue. Furthermore, CCR9 expression was significantly elevated in OvCa cell lines (OVCAR-3 and CAOV-3) in
comparison to normal adult ovarian epithelial cell mRNA. OvCa cells showed higher migratory and invasive
potential towards chemotactic gradients of CCL25, which was inhibited by anti-CCR9 antibodies. Expression of
collagenases (MMP-1, -8, and -13), gelatinases (MMP-2 and -9), and stromelysins (MMP-3, -10, and -11) by OvCa cells
were modulated by CCL25 in a CCR9-dependent fashion.
Conclusions: These results demonstrate both biological significance and clinical relevance of CCL25 and CCR9
interactions in OvCa cell metastasis.
Background
Ovarian Cancer (OvCa) is the fifth leading cause of can-
cer-related deaths among women in the United States
[1,2]. OvCa has been viewed as an intraperitoneal disease
that rarely spreads to other organs. However, recent
autopsy studies revealed a much higher rate of occult
metastasis, indicating extraperitoneal spread occurs with
much greater frequency than previously appreciated and
hematogenous dissemination of tumor cells occurs early
and throughout all stages of OvCa [3]. For metastasis to
occur, OvCa cells must disseminate from the primary
tumor, penetrate the basement membrane and invade the
interstitial stroma. Matrix metalloproteinases (MMPs) are
structurally and functionally related zinc-dependent endo-
peptidases that normally function in ovulation, wound
repair, and bone remodeling [4]. MMPs can be divided
into three distinct categories based on their structural and
functional properties: collagenases (MMP-1, -8, and -13),
gelatinases (MMP-2 and -9), and stromelysins (MMP-3,
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-10, and -11). Collagenases initiate degradation of several
naive fibrillar collagens. Gelatinases, also called type IV
collagenases, degrade collagen and basement membrane
components. Stromelysins can degrade a broad range of
substrates, including collagen, fibronectin, laminin, elastin
and proteoglycan core proteins [5]. High plasma and
ascites fluid levels of MMPs have been correlated with
OvCa progression and poor prognosis [6-8]. We have pre-
viously shown that CXCL12 and CCL25 can modulate the
expression of MMPs by prostate cancer cells [9,10].
Chemokines represent a super-family of small, chemo-
tactic cytokines that are involved in many inflammatory
processes. Many cancer cell types display restricted
expression of chemokine receptors [11,12]. CCR6 is
overexpressed by liver metastases of ovarian carcinomas,
suggesting CCL20-CCR6 interactions promote malig-
nant cancer cells to metastasize to the liver [13]. It has
also been shown that CXCL12 (stromal-derived factor,
SDF-1a) affects the growth and metastasis of OvCa cells
through interactions with CXCR4 [14]. Unfortunately,
CXCR4 is not a tumor-specific marker and its ligand,
CXCL12, is widely expressed by cells of the immune,
cardiovascular, and nervous systems. Moreover, this che-
mokine plays an important role in fetal development,
cardiovascular function, migration of hematopoietic
stem cells and trafficking of naïve lymphocytes [11].
Deletion of either CXCR4 or CXCL12 is lethal to the
embryo. Nonetheless, CXCL12-CXCR4 interactions
enhanced intraperitoneal dissemination of OvCa cells
[15], in part through activating MMP-2 and -9 [16].
CCL25 is mainly expressed by the thymus and small
bowel as well as by the spleen after challenge with lipo-
polysaccharide [17,18]. Unlike CXCR4 and CXCL12, the
deletion of either CCR9 or CCL25 genes is not lethal
[19]. Hence, there may be fewer toxicities associated with
therapies that target this axis. We show that CCR9 is
expressed at higher levels by human OvCa cells and tis-
sues in comparison to non-cancerous samples. Addition-
ally, we show that CCL25 modulates MMP expression
and enhances the migration and invasive potential of
OvCa cells. These findings suggest CCL25-CCR9 interac-
tion contribute to OvCa cell migration and invasion and
blocking this axis might inhibit OvCa cell metastasis.
Materials and methods
OvCa tissue microarray
OvCa tissue microarrays were obtained from the South-
ern Division of the Cooperative Human Tissue Network
(CHTN) and the University of Alabama at Birmingham.
To construct these tissue microarrays, at least two cores
(1 mm in diameter) per patient were arrayed on a recei-
ver blank paraffin block. A qualified pathologist con-
cerning the histopathology, the class and the grade of
the tumor validated each core of the tissue microarray
one additional time. The OvCa tissue microarray used
in this study was composed of tumors from 34 patients.
These ovarian tumors represented all histopathological
subtypes (8 non-neoplastic, 10 serous adenocarcinoma,
11 endometrioid adenocarcinoma, 5 mucinous adeno-
carcinoma) and every tumor grade of OvCa disease. The
tissue microarray was cut in 4 μm sections and placed
on super frost charged glass microscope slides.
Quantitation of immunohistochemical staining
To numerically analyze the immunohistochemical stain-
ing, virtual slides were created from stained samples
after scanning each specimen using an Aperio Scan-
Scope GL scanning system (Aperio Technologies). The
ScanScope GL system generated true color digital
images of each stained sample, which were viewed using
ImageScope version 6.25 software (Aperio Technolo-
gies). The ImageScope algorithm for determining the
intensity of membrane-specific staining was used to cal-
culate the staining intensity and percent target label for
each sample by digitally analyzing the color intensity.
The output of stain intensities ranging from 0 to 3 cor-
related with conventional manual scoring methods
(where 0 = negative and 3 = strong staining).
Cell culture
Human OvCa cell lines (OVCAR-3 and CAOV-3) were
obtained from the American Type Culture Collection
(ATCC). The cells were cultured in RPMI 1640 (Media-
tech, Inc.), supplemented with 10% fetal bovine serum
(FBS, Sigma) at 37°C with 5% CO2. Prior to each experi-
ment, cells were cultured for 24 hours in RPMI 1640
and 2% charcoal-striped FBS.
Primer design
Human mRNA sequences for CCR9, MMP-1, MMP-2,
MMP-3, MMP-7, MMP-8, MMP-9, MMP-10, MMP-11,
MMP-13 and 18 S rRNA were obtained from National
Center for Biotechnology Information (NCBI) Gen Bank
database accession numbers were XM003251, MM002421,
NM004530, NM002422, XM017384, NM002424,
NM04994, NM002425, NM005940, NM002427, and
X00686.1, respectively. These sequences were then used to
design primers for reverse transcription polymerase chain
reaction (RT-PCR) analysis, which generated amplicons of
162, 83, 95, 155, 169, 86, 79, 94, 107, 117, 176, and 149 bp
in size for CCR9, MMP-1, MMP-2, MMP-3, MMP-7,
MMP-8, MMP-9, MMP-10, MMP-11, MMP-12, MMP-13
mRNA and 18 S rRNA, respectively. Primers were
designed using the Primer 3 software program from the
Whitehead Institute at the Massachusetts Institute of
Technology. Thermodynamic analysis of the primers was
conducted using Primer PremierTM (Integrated DNA
Technologies) and MIT Primer III. The resulting primer
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sets were compared against the entire human genome to
confirm specificity and to ensure that the primers flanked
mRNA splicing regions.
RNA isolation and RT-PCR
Total RNA from OvCa cells was isolated using Tri-
Reagent, according to manufacturer’s protocols
(Molecular Research Center). Potential genomic DNA
contamination was removed from the samples by treat-
ment with RNase-free DNase (Invitrogen) for 15 minutes
at 37°C. RNA was precipitated and resuspended in RNA
Secure (Ambion). cDNA was generated by reverse tran-
scribing 1.5 μg of total RNA using iScript reagents
(BioRad) according to manufacturer’s protocol (BioRad).
cDNA was amplified with specific primers for CCR9,
MMP-1, MMP-2, MMP-3, MMP-7, MMP-8, MMP-9,
MMP-10, MMP-11, MMP-13 and 18 S rRNA using
SYBR Green polymerase chain reaction master mix
reagents (BioRad). PCR-Ready cDNA from normal adult
ovaries was obtained from Spring Bioscience. The num-
ber of copies (>5) of mRNA relative to 18S rRNA copies
of these targets was evaluated by RT-PCR analysis using
the BioRad Icycler and software. Hence, the number of
copies for each target was calculated using a standard
curve and data were normalized with copies of 18 S
rRNA expressed in each sample. The results are pre-
sented as the number of copies of target per 106 copies
of 18 S rRNA. Gene expression analysis experiments
were repeated twice.
Flow cytometry analysis of CCR9 surface expression
Phycoerythrin (PE)-conjugated mouse anti-human CCR9
(clone 112509) antibody and PE-conjugated mouse
IgG2a immunoglobulin isotype control (clone 20102)
was purchased from R&D Systems. OvCa cells were
washed three times in phosphate buffered saline (PBS)
[supplemented with 1% bovine serum albumin (BSA)]
and treated with 1.0 μg of Fc Block (PharMingen) per
105 cells for 15 minutes at room temperature. Fc-
blocked cells were stained with 1.0 μg of PE-conjugated
mouse anti-human CCR9 or PE-conjugated mouse
IgG2a isotype control antibody per 105 cells at 4°C for 1
hour. Subsequently, the cells were washed with 1.0 mL
of fluorescence-activated cell-sorting (FACS) buffer (1%
BSA in PBS) to remove unbound antibodies. Next,
labeled cells were fixed in 500 μL of 2% paraformalde-
hyde solution, and 105 cells were analyzed by flow cyto-
metry using a FACScan flow cytometer and CellQuest
software (BD PharMingen).
Migration and invasion assays
OvCa cell migration and Matrigel invasion chambers
were obtained from Becton Dickinson Discovery Lab-
ware. Serum free carbonate-base Dulbecco’s Modified
Eagle’s Medium (DMEM) was added to the bottom
chamber (750 μL) and top chamber (500 μL) of the
martigel inserts and allowed to hydrate for 2 hours at
37°C and 5% CO2. After hydration, media was gently
aspirated from bottom and top chambers, while 100 ng/
mL of CCL25 (PeproTech) or albumin (negative control)
was prepared in RPMI supplemented with charcoal
stripped FBS and 750 μl added to the bottom chamber.
Next, 104 cancer cells in 500 μL of RPMI with or with-
out 1 (g/mL of the mouse anti-human CCR9 (clone
112509, R&D Systems) or isotype control (clone 20102;
R&D Systems) antibodies were added to the top cham-
ber of the inserts and incubated overnight at 37°C with
5% CO2. After incubation, cells from the top chamber
were removed using a cotton-tipped swab. Cells that
migrated or invaded through and to the bottom surface
of the inserts were fixed with 100% methanol for 2 min-
utes, stained for 2 minutes in 1% toluidine blue (Sigma)
supplemented with 1% borax (Sigma) and rinsed twice
with distilled water. The cells were counted by micro-
scopy; migration and invasion studies were repeated
three times.
Active MMP detection
OvCa cells (105 per well) were seeded in 24-well plates
and treated with 0 or 100 ng/mL of CCL25, 1 μg/mL of
isotype control antibody or anti-CCR9 antibody, or cul-
ture media without cells. Conditioned media from the
untreated and treated cells were collected for subse-
quent analysis of active MMP expression. Flurokine
(R&D Systems) and Biotrak (GE healthcare) assay kits
were used to quantify active collagenases, gelatinases,
and stromelysins in the conditioned media, according to
manufacturer’s protocols.
Statistics
CCR9 expression intensity by ovarian TMAs was tested
for normality assumptions using the Shapiro-Wilk test
and transformed to a logit scale. The general linear
models (GLM) procedure was used to test the associa-
tion of CCR9 expression and disease condition using
SAS version 9.1.3 statistical analysis software. Results
were declared significant at a a level of 0.001. The
experimental data were compared using a two-tailed
Student’s t test and expressed as the mean ± SEM. The
results were analyzed using the Stat view II program
(Abacus Concepts, Inc.) and were labeled statistically
significant if p values were < 0.01. When MMP levels
were lower than the detectable limit of the assays, the
values were recorded as one-half of the minimum detec-
tion limit for statistical analysis. Using the Cell Quest
Software, the Kolmogorov-Smirnov (K-S) two-sample
test was used to calculate the statistical significance of
the CCR9 flow cytometry histograms.
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Results
Expression of CCR9 by OvCa tissue
Ovarian TMAs consisting of non-neoplastic, mucinous
adenocarcinoma, papillary serous carcinoma, and endome-
triod carcinoma tissues were evaluated for CCR9 expres-
sion. Positive staining was classified as 1 (missing or weak
expression), 2 (medium expression), or 3 (high expres-
sion). In general, OvCa tissues significantly (p < 0.001)
expressed CCR9 compared to non-neoplastic tissue, as did
papillary serous and endometroid carcinomas compared
to mucinous adenocarcinoma (Figure 1). The highest
expression of CCR9 was observed in endometriod carci-
noma followed by papillary serous carcinomas. While
CCR9 expression by mucinous adenocarcinoma was lower
than endometriod and papillary serous carcinomas, these
OvCa cases significantly (p < 0.001) expressed CCR9 com-
pared to non-neoplastic ovarian tissue.
CCR9 expression by OvCa cell lines
OvCa cell lines as well as non-neoplastic ovarian epithelial
cells were evaluated for CCR9 mRNA and OVCAR-3 and
CAOV-3 cell lines were characterized for CCR9 protein
expression. CCR9 mRNA was significantly (p < 0.01)
expressed by OVCAR-3 and CAOV-3 cell lines compared
to normal ovarian epithelial cells (Figure 2). CCR9 surface
protein expression was evaluated by flow cytometry. As
with mRNA expression, OvCa cell lines significantly
expressed CCR9 compared to controls. The mean fluores-
cent intensity of CCR9 expression for OVCAR-3 (M =
33.56) was significantly higher than CAOV-3 (M = 27.75).
CCL25-induced migration and invasion of OvCa cell lines
OvCa cell lines were tested for CCL25-dependent migra-
tion and invasion. CAOV-3 and OVCAR-3 cells signifi-
cantly migrated to CCL25, compared to media without
CCL25 (Figure 3). This CCL25-dependent chemotaxis
was neutralized by anti-CCR9 antibody treatment, but
not by the isotype control antibody. These findings
demonstrated the functional expression of CCR9 by
OvCa cells, which migrate to CCL25. CAOV-3 and
OVCAR-3 differentially invaded Matrigel in response to
CCL25. CAOV-3, but not OVCAR-3, cell lines signifi-
cantly invaded through Matrigel in response to CCL25.
As with migration responses, CCL25-mediated invasion
was CCR9-dependent since cell lines treated with anti-
CCR9 antibody behaved like controls. Interestingly, the
differences in cell invasion did not correlate with CCR9
expression, because OVCAR-3 cell lines expressed signif-
icantly more CCR9 than CAOV-3 cells.
CCL25-induced MMP expression by OvCa cells
To determine the mechanisms behind CCR9-dependent
OvCa cell invasion and the enhanced ability of CAOV-3
cells compared to OVCAR-3 cell lines to invade Matri-
gel in response to CCL25, we quantified the expression
of MMP mRNA and active protein. Both untreated and
CCL25-treated OVCAR-3 and CAOV-3 cell lines
expressed collagenases (MMP-1, -8, and -13) (Figure 4).
Compared to untreated cells, CCL25-treated OVCAR-3
cells significantly expressed MMP-8 and MMP-13
mRNAs and active proteins. While CCL25 treatment of
CAOV-3 cells did not affect collagenase mRNA expres-
sion, CCL25-treated CAOV-3 cells significantly
expressed MMP-1 and -8 active protein, compared to
untreated controls or CCL25-treated cells co-incubated
with anti-CCR9 antibody. However, MMP-13 mRNA
and active protein expression by CAOV-3 cells was not
affected by CCL25 stimulation.
MMP-2 mRNA expression and active protein were
expressed by all OvCa cell lines (Figure 5). Following
CCL25 treatment, OVCAR-3 cells significantly
expressed MMP-2 and -9 mRNA as well as active pro-
tein compared to untreated cells. This gelatinase pro-
duction was abrogated by anti-CCR9 antibody. MMP-9
mRNA and active protein by CAOV-3 cells was mar-
ginal and not affected by CCL25. While CCL25 treat-
ment did not induce MMP-2 mRNA expression, active
MMP-2 protein was generated after CCL25 stimulation;
this increase was inhibited by anti-CCR9 antibody.
Untreated OVCAR-3 and CAOV-3 cells expressed
mRNA and active protein of stromelysins (Figure 6). To
this end, untreated CAOV-3 cells produced more
MMP-10 and -11 mRNA and active protein than
OVCAR-3 cells. CCL25 treatment of OVCAR-3 cells
induced large increases in MMP-3, -10, and -11 mRNAs
and active proteins, while CCL25 treatment of CAOV-3
cells resulted in selective yet significant increases in
active MMP-3 and -10 secretion.
Discussion
Late diagnosis and metastasis are major causes for the
high mortality rate of OvCa [1]. Chemokines have been
shown to play important roles in organ-specific homing
of cancer cells to distant organs [12,20]. CCL25-CCR9
interactions are key to leukocyte homing to the small
bowel [21,22], a common and fatal site of OvCa metas-
tasis. In this regard, high levels of CCL25 in the gut
mucosa and expression of CCR9 by OvCa cell lines sug-
gest CCL25-CCR9 interactions might play a significant
role in the mucosal homing of OvCa cells.
While metastasis of well-differentiated endometrioid
adenocarcinoma are typically limited to the uterine
body, mildly and poorly differentiated invasive endome-
troid adenocarcinomas have been associated with cervi-
cal invasion and distal metastasis [23]. Serous papillary
carcinoma is an aggressive form of endometrial cancer
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Figure 1 CCR9 expressed by ovarian cancer tissue. Ovarian cancer tissues from non- neoplastic (n = 8), mucinous adenocarcinoma (n = 5),
serous papillary carcinoma (n = 10), and endometroid carcinoma (n = 11) were stained with isotype control or anti-CCR9 antibodies. Brown
(DAB) color show CCR9 staining. An Aperio ScanScope CS system with a 40× objective captured digital images of each slide. Representative
cases are indicated and immuno-intensities of CCR9 were quantified using image analysis Aperio ImageScope v.6.25 software. CCR9 expression
by tissues were analyzed and presented by modified box plot. Lower, middle and upper lines, respectively, in the box represent the first quartile
(Q1), Median (Q2) and third quartile (Q3). Upper (T) and lower (⊥) whiskers are represented by median ± 1.5 (Q3-Q1). Significant differences from
non-neoplastic are indicated with a solid star whereas significant differences between mucinous adenocarcinoma and serous papillary as well as
endometroid carcinomas are indicated with a white star in a black circle.
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that is likely to present with deep myometrial invasion
and lymph vascular involvement. By the time most
affected women are diagnosed, serous papillary carci-
noma often spreads outside the uterus. Serous endome-
trial intra-epithelial carcinoma is a recently recognized
entity with the same cytological features and p53 muta-
tions as uterine serous carcinoma, with the former asso-
ciated with stromal and/or myometrial invasion and
extra-uterine metastasis. Interestingly, we found the
highest expression of CCR9 in serous papillary and
endometroid carcinomas in comparison to non-neoplas-
tic and to a lesser degree in mucinous adenocarcinoma
cases. Given the poor prognosis of serous papillary and
endometroid carcinoma, our data supports the develop-
ment of therapies that target the CCL25-CCR9 axis.
Indeed, CCR9 blockade inhibited migration, MMP pro-
duction, and invasion of OvCa cell lines.
CCL25-CCR9 interactions have been previously impli-
cated in the progression of melanoma and prostate can-
cers [10,24]. Other studies concluded CCR9 is highly
expressed by melanoma cells and all melanoma cells iso-
lated from small intestine metastases [25]. Here we
show for the first time that normal ovarian epithelial
cells and non-neoplastic tissues express low levels of
CCR9, while OvCa cell lines and mucinous adenocarci-
noma, papillary serous carcinoma, and endometriod car-
cinoma tissues express high levels of CCR9. While
ovulating ovaries express CCR9 and CCL25, which play
important role during ovulation [26], we show that the
expression of CCR9 mRNA by OvCa cell lines is signifi-
cantly higher than levels expressed by normal adult
ovarian epithelial cells. Each of the OvCa cell lines
exhibited significantly higher CCL25-mediated migration
and invasion, which was CCR9-dependent.
Figure 2 CCR9 mRNA and cell surface protein expressed by
ovarian cancer cells. Total RNA was isolated from OVCAR-3 and
CAOV-3 cell lines and normal primary ovary tissue. Quantitative RT-
PCR analysis of CCR9 mRNA expression was performed in triplicate.
The copies of transcripts are expressed relative to actual copies of
18 S rRNA ± SEM. OVCAR-3 and CAOV-3 cells were stained with PE-
conjugated isotype control antibodies (solid histogram) or PE-
conjugated anti-CCR9 monoclonal antibodies (open histogram) and
quantified by flow cytometry. The mean fluorescent intensities of
PE-positive cells are shown. Asterisk(s) indicate statistical significance
(p < 0.01) between normal tissue and OvCa cells.
Figure 3 CCR9-mediated ovarian cancer cell migration and
invasion. (A) OVCAR-3 and CAOV-3 cells were tested for their ability
to migrate toward chemotactic gradients of CCL25. Cells were co-
cultured with 1.0 μg/mL mouse anti-CCR9 antibody during
migration assays using 100 ng/mL of CCL25. (B) OVCAR-3 and
CAOV-3 cells were also tested for their ability to invade or
translocate across Matrigel™ matrix in response to 100 ng/mL of
CCL25. Cells were co-cultured with 1.0 μg/mL monoclonal
antibodies against CCR9 during invasion assays using 100 ng/mL of
CCL25. The number of cells ± SEM that migrated or invaded is
shown with asterisk(s) that indicate significant differences (p < 0.01)
between no additions and chemokine-induced cells.
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Among the numerous OvCa cell lines studied, CAOV-
3 and OVCAR-3 have the highest incidence and average
metastatic frequency [27]. CAOV-3 is an invasive
human ovarian papillary carcinoma cell line. While the
histological phenotype of the OVCAR-3 cell line is
unknown, it was established from the malignant ascites
of a patient with progressive adenocarcinoma of the
ovary. OVCAR-3 xenografts produce either ascites or
solid tumors in the peritoneal cavity [28], but similar
grafts using the more invasive CAOV-3 cell line result
in lung and other organ metastasis [27]. Neoplastic cells
must penetrate the basement membrane and invade the
interstitial stroma to initiate the metastatic process. To
this end, many proteinases are capable of degrading
extracellular matrix (ECM) components, but MMPs
appear to be particularly important for matrix degrada-
tion [29,30] and cancer cell dissemination [31].
Collagenases (MMP-1, MMP-8 and MMP-13) initiate
degradation of several naïve fibrillar collagens, including
type-I, -II and -III. Higher expression of MMP-1 has
been correlated with progression and poor survival in
bladder cancer [32]. In most instances, increased expres-
sion of MMP-1 has a significant negative correlation
with survival. Similarly, over production of MMP-8 has
been shown to contribute to the invasive potential of
OvCa [33]. Indeed, MMP-8 expression significantly cor-
related with ovarian tumor grade, tumor stage, and poor
prognosis [34]. Even though CAOV-3 cells expressed
slightly less CCR9 than OVCAR-3 cells, CCL25 treat-
ment resulted in significant MMP-1 and -8 mRNA and
active protein expression by CAOV-3 >> OVCAR-3 cell
lines. On the other hand, MMP-13 is important for the
degradation of type-I and -II collagens and its presence
in ascites fluid has been used to identify patients at risk
for early death from OvCa [7]. MMP-13 has been well
documented in many aggressive cancers, but its expres-
sion is most often seen only in the invading front of
tumors [35,36]. While OVCAR-3 cell supernatants
expressed more MMP-13 in response to CCL25 treat-
ment, the more invasive CAOV-3 cells did not produce
MMP-13 mRNA or active protein in response to this
CCR9 ligand. Possibly, MMP-13 is differentially
Figure 4 CCL25-induced collagenase expression by ovarian
cancer cells. Cells were tested for their ability to express
collagenases (MMP-1, MMP-8, and MMP-13) mRNA and protein.
OVCAR-3 and CAOV-3 cells were cultured for 24 hours alone, with
100 ng/mL of CCL25, or CCL25 + 1 μg/mL of mouse anti-CCR9
antibody. Total RNA was isolated and quantitative RT-PCR analysis
was performed for mRNA expression of collagenases (upper panel)
and transcript copies are presented relative to actual copies of 18 S
rRNA. Active collagenases were quantified by Fluorokine and Biotrak
assays in conditioned media (lower panel). MMP expression below
the detectable limit of the RT-PCR is designated as below detection
(BD). Asterisk(s) indicate statistical differences (p < 0.01) between
untreated and CCL25-treated OvCa cells.
Figure 5 CCL25-induced gelatinase expression by ovarian
cancer cells. Cells were tested for their ability to express
gelatinases (MMP-2 and MMP-9) mRNA and protein. OVCAR-3 and
CAOV-3 cells were cultured for 24 hours alone, with 100 ng/mL of
CCL25, or 100 ng/mL of CCL25 + 1 μg/mL of monoclonal
antibodies against CCR9. Total RNA was isolated and quantitative
RT-PCR analysis was performed for mRNA expression of gelatinases
(upper panel) and transcript copies are presented relative to actual
copies of 18 S rRNA. Active gelatinases in conditioned media were
quantified by Fluorokine and Biotrak assays (lower panel). MMP
expression below the detectable limit of the RT-PCR is designated
as below detection (BD). Asterisk(s) indicate statistical differences (p
< 0.01) between untreated and CCL25-treated OvCa cells.
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expressed by OvCa cells and not crucial for ovarian
tumor invasiveness per se.
Gelatinase-A and -B (MMP-2 and -9), also called type
IV collagenases, degrade gelatin, collagen and other
basement membrane components. High levels of MMP-
2 and -9 have been associated with many diseases,
including OvCa, and correlate with poor prognosis [37].
In an immunohistochemical study of malignant ovarian
tissues, positive staining of MMP-2 was associated with
poor survival [38]. In the present study, OVCAR-3 and
CAOV-3 cell lines expressed MMP-2 mRNA and active
protein. Importantly, CCL25 treatment led to a signifi-
cant increase in MMP-2 expression by both OvCa cell
lines. MMP-9 is frequently up regulated by cancer cells
and has been shown to affect tumor metastasis and pro-
gression. CCL25 treatment induced an increase in
MMP-9 expression by OVCAR-3, but not CAOV-3
cells. Perhaps, the lack of active MMP-9 expression by
these cell lines is due to the production of high levels of
tissue inhibitors of metalloproteinases (TIMPs). TIMPs
are major regulators of matrix metalloproteinase activity.
Specifically, TIMP-1 preferably binds and inactivates
MMP-9 [39]. In this regard, high circulating TIMP-1
correlated to the aggressive phenotype and unfavorable
prognosis of malignant neoplasias [39]. Therefore, it is
possible that the CAOV-3 cell lines express elevated
levels of TIMP-1, which would inhibit the generation of
active MMP-9 protein.
Stromelysins (MMP-3, -10, and -11) are typically
expressed by normal epithelial cells and degrade a vari-
ety of substrates, including type IV, V, IX AND X col-
lagens, fibronectin, laminin, elastin, and proteoglycan
core proteins. Many carcinomas express stromelysins;
for example, MMP-3 and -10 produced by the head and
neck carcinomas are higher than in normal-matched tis-
sue [40]. In this study, MMP-3 and MMP-10 mRNA
and protein were expressed at significantly higher levels
by OVCAR-3 and CAOV-3 cell lines, after CCL25 treat-
ment. CCR9 activation also led to an elevation of MMP-
11 mRNA and active protein expression by OVCAR-3
cells. Indeed, MMP-11 (or stromelysin-3) expression is
more frequently observed in malignant ovarian carcino-
mas than tumors with low malignant potential [41].
Our study shows that the OvCa cell lines, OVCAR-3
and CAOV-3, differentially expressed MMPs that are
important for OvCa metastasis after CCL25 stimulation.
While OVCAR-3 and CAOV-3 cell lines were both
established from malignant ascites [42], these cell lines
selectively migrated chamber inserts and invaded Matri-
gel in response to CCL25. For example, OVCAR-3, but
not CAOV-3, cells poorly attached to host-tissue sur-
faces and express lamin receptor [43]. While these
responses were CCR9-dependent, other factors no doubt
contribute to their abilities to migrate and invade tissue
extracellular matrix components.
Conclusions
We provide the first evidence that OvCa cells express
functional CCR9. The effect of CCL25 on MMP expres-
sion suggests that this chemokine plays a role in ovarian
tumor cell invasion via MMP modulation. Our results,
along with selective expression of CCL25 in the small
bowel, support our hypothesis that OvCa cell migration
and invasion are in part mediated by CCL25-CCR9
interactions. Additional studies will be necessary to eval-
uate the other possible cellular and molecular mechan-
isms mediated by CCL25 that support OvCa cell
migration and invasion.
Acknowledgements
The content of this manuscript benefited from many fruitful conversations
with members of the Morehouse School of Medicine, the University of
Alabama at Birmingham. This study was supported by National Institute of
Figure 6 CCL25-induced stromelysin expression by ovarian
cancer cells. Cells were tested for their ability to express
stromelysins (MMP-3, MMP-10, and MMP-11) mRNA and protein.
OVCAR-3 and CAOV-3 cells were cultured for 24 hours alone, with
100 ng/mL of CCL25, or 100 ng/mL of CCL25 + 1 μg/mL of
monoclonal antibodies against CCR9. Total RNA was isolated and
quantitative RT-PCR analysis was performed for mRNA expression of
stromelysins (upper panel) and transcript copies are presented
relative to actual copies of 18 S rRNA. Active stromelysins were
quantified by Fluorokine and Biotrak assays in conditioned media
(lower panel). MMP expression below the detectable limit of the RT-
PCR is designated as below detection (BD). Asterisk(s) indicate
statistical differences (p < 0.01) between untreated and CCL25-
treated OvCa cells.
Johnson et al. World Journal of Surgical Oncology 2010, 8:62
http://www.wjso.com/content/8/1/62
Page 8 of 10
Health grants CA092078, CA086359, DK58967, GM08248, MD00525, and
RR03034.
Author details
1Department of Microbiology, Biochemistry, & Immunology, Morehouse
School of Medicine, 720 Westview Drive SW, Atlanta, GA 30310-1495, USA.
2Department of Pathology, University of Alabama at Birmingham, 703 19th
Street South, Birmingham, AL 35294-0007, USA. 3Department of Obstetrics &
Gynecology, Division of Gynecological Oncology, 618 20th Street South,
University of Alabama at Birmingham, Birmingham, AL 35233-7333, USA.
Authors’ contributions
ELJ conducted the experiments and drafted the manuscript. RS analyzed the
data and assisted with manuscript preparation. CMJH, WEG, EEP, and SS
assisted during the experiments and manuscripts preparation. JWL
conceptualized, edited, and revised the manuscript. All authors have read
and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 19 February 2010 Accepted: 22 July 2010
Published: 22 July 2010
References
1. Cvetkovic D: Early events in ovarian oncogenesis. Reprod Biol Endocrinol
2003, 1:68.
2. Wong A, Auersperg N: Ovarian surface epithelium: family history and
early events in ovarian cancer. Reprod Biol Endocrinol 2003, 1:70.
3. Braun S, Schindlbeck C, Hepp F, Janni W, Kentenich C, Riethmuller G,
Pantel K: Occult Tumor Cells in Bone Marrow of Patients With
Locoregionally Restricted Ovarian Cancer Predict Early Distant Metastatic
Relapse. J Clin Oncol 2001, 19:368-375.
4. Yoon S, Park S, Yun C, Chung A: Roles of Matrix Metallo-proteinases in
Tumor Metastasis and Angiogenesis. J Biochem Mol Biol 2003, 36:128-137.
5. Myriam P, Béatrice N-R, Christine G, Christine C, Philippe B: Tumour
invasion and matrix metalloproteinases. Crit Rev Oncol Hematol 2004,
49:179.
6. Demeter A, Sziller I, Csapo Z, Olah J, Keszler G, Jeney A, Papp Z, Staub M:
Molecular prognostic markers in recurrent and in non-recurrent
epithelial ovarian cancer. Anticancer Res 2005, 25:2885-2889.
7. Hantke B, Harbeck N, Schmalfeldt B, Claes I, Hiller O, Luther M-O, Welk A,
Kuhn W, Schmitt M, Tschesche H, Muehlenweg B: Clinical relevance of
matrix metalloproteinase-13 determined with a new highly specific and
sensitive ELISA in ascitic fluid of advanced ovarian carcinoma patients.
Biol Chem 2003, 384:1247-1251.
8. Manenti L, Paganoni P, Floriani I, Landoni F, Torri V, Buda A, Taraboletti G,
Labianca R, Belotti D, Giavazzi R: Expression levels of vascular endothelial
growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of
metalloproteinases 1 and 2 in the plasma of patients with ovarian
carcinoma. Eur J Cancer 2003, 39:1948-1956.
9. Singh S, Singh UP, Grizzle WE, Lillard JW: CXCL12-CXCR4 interactions
modulates prostate cancer cell migration, metalloproteinase expression
and invasion. Lab Invest 2004, 84:1666-1676.
10. Singh S, Singh UP, Stiles JK, Grizzle WE, Lillard JW: Expression and
Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion.
Clin Cancer Res 2004, 10:8743-8750.
11. Kulbe H, Levinson NR, Balkwill F, Wilson JL: The chemokine network in
cancer–much more than directing cell movement. Int J Dev Biol 2004,
48:489-496.
12. Strieter RM: Chemokines: Not just leukocyte chemoattractants in the
promotion of cancer. Nat Immunol 2001, 2:285.
13. Dellacasagrande J, Schreurs OJ, Hofgaard PO, Omholt H, Steinsvoll S,
Schenck K, Bogen B, Dembic Z: Liver metastasis of cancer facilitated by
chemokine receptor CCR6. Scand J Immunol 2003, 57:534-544.
14. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F: Involvement
of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of
epithelial ovarian carcinoma. Int J Cancer 2008, 122:91-99.
15. Kajiyama H, Shibata K, Terauchi M, Ino K, Nawa A, Kikkawa F: Involvement
of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of
epithelial ovarian carcinoma. Int J Cancer 2008, 122:91-99.
16. Yuecheng Y, Xiaoyan X: Stromal-cell derived factor-1 regulates epithelial
ovarian cancer cell invasion by activating matrix metalloproteinase-9
and matrix metalloproteinase-2. Eur J Cancer Prev 2007, 16:430-435.
17. Yu Q, Stamenkovic I: Cell surface-localized matrix metalloproteinase-9
proteolytically activates TGF-beta and promotes tumor invasion and
angiogenesis. Genes Dev 2000, 14:163-176.
18. Papadakis KA, Prehn J, Nelson V, Cheng L, Binder SW, Ponath PD,
Andrew DP, Targan SR: The role of thymus-expressed chemokine and its
receptor CCR9 on lymphocytes in the regional specialization of the
mucosal immune system. J Immunol 2000, 165:5069-5076.
19. Wurbel M-A, Malissen M, Guy-Grand D, Meffre E, Nussenzweig MC,
Richelme M, Carrier A, Malissen B: Mice lacking the CCR9 CC-chemokine
receptor show a mild impairment of early T- and B-cell development
and a reduction in T-cell receptor gamma delta + gut intraepithelial
lymphocytes. Blood 2001, 98:2626-2632.
20. Müller A, Homey B, Soto H, Ge N, Catron D, Buchanan ME, McClanahan T,
Murphy E, Yuan W, Wagner SN, Barrera JL, Mohar A, Verástegui E, Zlotnik A:
Involvement of chemokine receptors in breast cancer metastasis. Nature
2001, 410:50-56.
21. Koenecke C, Forster R: CCR9 and inflammatory bowel disease. Expert Opin
Ther Targets 2009, 13:297-306.
22. Kabelitz D, Wesch D: Features and functions of gamma delta T
lymphocytes: focus on chemokines and their receptors. Crit Rev Immunol
2003, 23:339-370.
23. Morarescu MD, Simionescu C, Rosculescu I, Bala S, Cernea N, Patru E:
Histopatological aspects of endometroid carcinoma in correlation to the
state of tumoral progression in women patients during their
premenopausal period. Rom J Morphol Embryol 2006, 47:53-58.
24. Hwang ST: Chemokine receptors in melanoma: CCR9 has a potential role
in metastasis to the small bowel. J Invest Dermatol 2004, 122:xiv-xv.
25. Letsch A, Keilholz U, Schadendorf D, Assfalg G, Asemissen AM, Thiel E,
Scheibenbogen C: Functional CCR9 expression is associated with small
intestinal metastasis. J Invest Dermatol 2004, 122:685-690.
26. Zhou C, Wu J, Borillo J, Torres L, McMahon J, Bao Y, Lou YH: Transient
expression of CC chemokine TECK in the ovary during ovulation: its
potential role in ovulation. Am J Reprod Immunol 2005, 53:238-248.
27. Gao QL, Ma D, Meng L, Wang SX, Wang CY, Lu YP, Zhang AL, Li J:
Association between Nm23-H1 gene expression and metastasis of
ovarian carcinoma. Ai Zheng 2004, 23:650-654.
28. Veatch AL, Carson LF, Ramakrishnan S: Phenotypic variations and
differential migration of NIH:OVCAR-3 ovarian carcinoma cells isolated
from athymic mice. Clin Exp Metastasis 1995, 13:165-172.
29. Hulboy DL, Rudolph LA, Matrisian LM: Matrix metalloproteinases as
mediators of reproductive function. Mol Hum Reprod 1997, 3:27-45.
30. Nagase H, Woessner JF Jr: Matrix metalloproteinases. J Biol Chem 1999,
274:21491-21494.
31. Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interactions
with the extracellular matrix during invasion and metastasis. Annu Rev
Cell Biol 1993, 9:541-573.
32. Durkan GC, Nutt JE, Tajjayabun PH, Neal DE, Lunec J, Mellon JK: Prognostic
significance of matrix metalloproteinase-1 and tissue inhibitor of
metalloproteinase-1 in voided urine samples from patients with
transitional cell carcinoma of the bladder. Clin Cancer Res 2001,
7:3450-3456.
33. Brinckerhoff CE, Rutter JL, Benbow U: Interstitial Collagenases as Markers
of Tumor Progression. Clin Cancer Res 2000, 6:4823-4830.
34. Stadlmann S, Pollheimer J, Moser PL, Raggi A, Amberger A, Margreiter R,
Offner FA, Mikuz G, Dirnhofer S, Moch H: Cytokine-regulated expression of
collagenase-2 (MMP-8) is involved in the progression of ovarian cancer.
Eur J Cancer 2003, 39:2499-2505.
35. Johansson N, Vaalamo M, Grenman S, Hietanen S, Klemi P, Saarialho-Kere U,
Kahari V-M: Collagenase-3 (MMP-13) is Expressed by Tumor Cells in
Invasive Vulvar Squamous Cell Carcinomas. Am J Pathol 1999,
154:469-480.
36. Balbin M, Pendas AM, Uria JA: Expression and regulation of collagenase-3
(MMP-13) in human malignant tumors. APMIS 1999, 107:45-53.
37. Sehgal A, Keener C, Boynton AL, Warrick J, Murphy GP: CXCR-4, a
chemokine receptor, is overexpressed in and required for proliferation
of glioblastoma tumor cells. J Surg Oncol 1998, 69:99-104.
38. Schmalfeldt B, Prechtel D, Harting K, Spathe K, Rutke S, Konik E, Fridman R,
Berger U, Schmitt M, Kuhn W, Lengyel E: Increased Expression of Matrix
Johnson et al. World Journal of Surgical Oncology 2010, 8:62
http://www.wjso.com/content/8/1/62
Page 9 of 10
Metalloproteinases (MMP)-2, MMP-9, and the Urokinase-Type
Plasminogen Activator Is Associated with Progression from Benign to
Advanced Ovarian Cancer. Clin Cancer Res 2001, 7:2396-2404.
39. Rauvala M, Puistola U, Turpeenniemi-Hujanen T: Gelatinases and their
tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a
prognostic factor. Gynecol Oncol 2005, 99:656-663.
40. Birkedal-Hansen B, Pavelic ZP, Gluckman JL, Stambrook P, Li YQ, Stetler-
Stevenson WG: MMP and TIMP gene expression in head and neck
squamous cell carcinomas and adjacent tissues. Oral Dis 2000, 6:376-382.
41. Mueller J, Brebeck B, Schmalfeldt B, Kuhn W, Graeff H, Hofler H:
Stromelysin-3 expression in invasive ovarian carcinomas and tumours of
low malignant potential. Virchows Arch 2000, 437:618-624.
42. Hamilton TC, Young RC, McKoy WM, Grotzinger KR, Green JA, Chu EW,
Whang-Peng J, Rogan AM, Green WR, Ozols RF: Characterization of a
Human Ovarian Carcinoma Cell Line (NIH:OVCAR-3) with Androgen and
Estrogen Receptors. Cancer Res 1983, 43:5379-5389.
43. Liebman JM, Burbelo PD, Yamada Y, Fridman R, Kleinman HK: Altered
expression of basement-membrane components and collagenases in
ascitic xenografts of OVCAR-3 ovarian cancer cells. Int J Cancer 1993,
55:102-109.
doi:10.1186/1477-7819-8-62
Cite this article as: Johnson et al.: CCL25-CCR9 interaction modulates
ovarian cancer cell migration, metalloproteinase expression, and
invasion. World Journal of Surgical Oncology 2010 8:62.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Johnson et al. World Journal of Surgical Oncology 2010, 8:62
http://www.wjso.com/content/8/1/62
Page 10 of 10
